BTK and mantle cell lymphoma: Although off-target effects were lower with Orelabrutinib, similar adverse effects were reported.[29] Therefore It is recommended that MCL patients should check the skin status, such as the change of skin color and the presence of plaques, every 3 months during the use of BTK inhibitors.